Locally Advanced and Metastatic Advances

Explains PET staging, chemoradiation with weekly cisplatin and brachytherapy, KEYNOTE A18 adding pembrolizumab, frontline metastatic platinum±bevacizumab plus immunotherapy, atezolizumab option, and tisotamab‑vedotin as a new second-line ADC.